Skip to content

UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue

UHR-OCT and HD-OCT for Preretinal Membranes: Is There a Difference Between ICG and Membrane Blue? A Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00437593
Enrollment
20
Registered
2007-02-21
Start date
2005-09-30
Completion date
2008-05-31
Last updated
2008-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Diseases

Keywords

preretinal membrane, vitrectomy, uhr-oct, hd-oct

Brief summary

Using the UHR-OCT and HD-OCT to evaluate early postoperative changes in patients with diagnosis preretinal membrane after successfully performed pars-plana vitrectomy and membrane peeling with two different types of dyes.

Detailed description

Surgical procedures performed are pars-plana vitrectomy and membrane peeling with or without cataract extraction and IOL implantation. The type of the dyes is randomized. The study is designed to include a total of tweny cases (10 cases with ICG and 10 cases with Membrane blue) Main outcome measures are: UHR-OCT, HD-OCT distance and near visual acuity and contrast sensitivity amsler grid secondary outcome measures are: OCT Stratus 3000 and visual field. Clinical examinations: preoperative, and follow-up examinations after 1 week, 1 months, 3 months, 6 months and 12 months.

Interventions

PROCEDUREppVE, MP, ICG

surgery with ILM staining

PROCEDUREppVE, MP, MB

Surgery with ERM staining

Sponsors

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Preretinal membrane * Age between 18 and 85 years * Combined surgery possible(phacoemulsification and vitreoretinal procedure)

Exclusion criteria

* Age-related macular degeneration * Previous retinal detachment surgery * Previous laser treatment

Design outcomes

Primary

MeasureTime frame
UHR-OCT HD-OCT12 months
Distance Visual acuity12 months
Near Visual acuity12 months
Contrast sensitivtiy12 months

Secondary

MeasureTime frame
OCT Stratus 300012 months
Visual Field12 months

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026